The past 5–10 years have brought in a new era in the care of patients with thyroid
cancer, with the introduction of transformative diagnostic and management options.
Several international ultrasound-based thyroid nodule risk stratification systems
have been developed with the goal of reducing unnecessary biopsies. Less invasive
alternatives to surgery for low-risk thyroid cancer, such as active surveillance and
minimally invasive interventions, are being explored. New systemic therapies are now
available for patients with advanced thyroid cancer.
Ipsen: ASCO 2022: New Cabometyx® Data Show Encouraging Results in Monotherapy and in Combination Across Different Tumor Types Including Metastatic Non-Small Cell Lung Cancer streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
COSMIC-021 Phase Ib study is evaluating Cabometyx (cabozantinib) in combination with atezolizumab in advanced solid tumors, including non-small cell lung cancer New analyses from pivotal Phase
Approval based on data from the COSMIC-311 Phase III trial, in which Cabometyx (cabozantinib) demonstrated a 78% reduction in risk of disease progression or death versus placebo1 This milestone